SCHEMBL23218538

SCHEMBL23218538

CCOC(=O)Cc1ccc(C)cc1OCc1coc2c(OCC3CC3)cc(Br)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.36
PIM1 P11309 2/20 0.36
PIM2 Q9P1W9 2/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 2/20 0.33
CNR2 P34972 1/20 0.33
P2RX3 P56373 1/20 0.32
PDCD1 Q15116 4/20 0.32
CD274 Q9NZQ7 4/20 0.32
MAPT P10636 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31
F2 P00734 1/20 0.31
GPBAR1 Q8TDU6 1/20 0.31
TP53 P04637 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853118 1.00 PDE10A (0.36) PDE10APIM1PIM2MEN1KMT2A
SCHEMBL23218138 0.91 MEN1 (0.35) PDE10APIM1PIM2MEN1KMT2A
SCHEMBL29853155 0.91 MEN1 (0.35) PDE10APIM1PIM2MEN1KMT2A
SCHEMBL29853204 0.90 PIM1 (0.36) PIM1PIM2CNR2PDCD1CD274
SCHEMBL23218843 0.90 PIM1 (0.36) PIM1PIM2CNR2PDCD1CD274
SCHEMBL23218781 0.87 ALDH1A1 (0.38) MEN1KMT2APOLBGAATSHR
SCHEMBL29852880 0.87 ALDH1A1 (0.38) MEN1KMT2APOLBGAATSHR
SCHEMBL23218724 0.85 MEN1 (0.38) MEN1KMT2APOLBGAATSHR
SCHEMBL29852746 0.85 MEN1 (0.38) MEN1KMT2APOLBGAATSHR
SCHEMBL23218179 0.83 CFD (0.40) PDE10AMEN1KMT2APOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PDE10A 3742/4885PIM1 4538/4885PIM2 4286/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PDE10A 3215/4885PIM1 4497/4885PIM2 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.